Abstract
Aim The overall aim of this project is to determine if gene expression signatures of tumors, constructed from geometrical attributes of data, could be used to predict patient treatment response by detecting subgroups of responders. This is tested in Pfizer clinical trial data and compared with standard clustering methods (n = 726).
Results Geometrical gene expression signature analysis demonstrated high utility to detect sub-groups with enhanced treatment response. In the Pfizer trial, gene expression signatures were able to detect three subgroups of responders (p = 0.012), containing 52.9% of patients and accounting for nearly all the observed treatment effect. Standard techniques following a similar methodology were able to partition a single subgroup containing 21.3% of patients.
Conclusions Gene expression based geometrical signatures yielded vastly superior performance over standard clustering techniques, as demonstrated in Pfizer’s Phase III clinical trial data. These can be used to determine subgroups of enhanced treatment response in oncology clinical trials, and might lead to personalized treatment recommendations in the future.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; WC and RR own equity in DatAnon Corporation which owns the codebase and related IP; no other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
NCT02684006
Funding Statement
WC was partially supported by VR, the Wallenberg AI, Autonomous System and Software Program (WASP) funded by Knut and Alice Wallenberg Foundation, and MultipleMS funded by the European Union under the Horizon 2020 program, grant agreement 733,161.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used open-sourced data from Pfizer's avelumab plus axitinib Phase III clinical trial in advanced renal cell carcinoma. The links are provided in the text, and the data can be freely downloaded.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
wojtek{at}kth.se
Added ORCID links and corrected language with permuted p-value to indicate it measured all tests equal to or greater than the observed effect.
Data Availability
The data in the present study were open-sourced by Pfizer and available online at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493486/
